Q-omics provides the consensus-scored TRMT1L profile across patient tissues and cancer cell-line models. TRMT1L expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TRMT1L is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, TRMT1L protein abundance shows 28,179 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, THCA, and LSCC as cancer lineages where TRMT1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRMT1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRMT1L survival associations across molecular data types. TRMT1L RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRMT1L RNA expression–survival associations across cancer types. High TRMT1L expression shows unfavorable associations in KIRP, DLBC, SCLC and UVM, but favorable associations in KIRC and CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TRMT1L RNA expression.
This table summarizes TRMT1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 10. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TRMT1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRMT1L shows lower tumor expression in THCA, KICH and UCEC and higher tumor expression in LIHC, BRCA and HNSC. The THCA box plot shows higher TRMT1L RNA expression in normal versus tumor tissue (log2 FC = −0.593, t-test p < 0.001).
This table shows molecular features associated with TRMT1L in patient tissues and cancer cell lines. In patient samples, TRMT1L shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRMT1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
